Default object view. Click to create a custom template, Node ID: 102709, Object ID: 61639

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung c...

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

No relation

Yes

No relation

No

26/02/2015 9:18 am

No